Pharmacological properties of the enantiomers of idazoxan: possible separation between their alpha-adrenoceptor blocking effects

Therapeutic use of release-modifying drugs

Presynaptic inhibitory or facilitatory autoreceptors are targets for the endogenous neurotransmitter of the respective neuron, and also for exogenous agonists, partial agonists and antagonists which can produce pharmacological actions through changes in transmitter release. In addition, presynaptic inhibitory or facilitatory heteroreceptors can also be acted upon by exogenous agonists, partial agonists or antagonists to induce changes in transmitter release with useful therapeutic effects. This article summarizes drugs that are known or likely to produce their therapeutic effects through presynaptic modulation of neurotransmitter release. Included are drugs acting on alpha and beta adrenoceptors, dopamine receptors, angiotensin, opioid, cannabinoid, and nicotinic acetylcholine receptors. Also discussed are changes in presynaptic receptor mechanisms produced by drugs that inhibit transmitter re-uptake.

Changes in serotonin metabolism in the rat raphe magnus and cardiovascular modifications following systemic administration of clonidine and other central alpha 2-agonists: an in vivo voltammetry study

By using the in vivo voltammetry, it was demonstrated that an injection of clonidine induced both cardiovascular modifications (hypotension and bradycardia) and a decrease in the level of 5-hydroxyindolacetic acid (5-HIAA) in the ventromedial B3 serotonergic (5-HT) cell bodies of the medulla oblongata of the rat. The cardiovascular effects of clonidine and of two other imidazolic compounds (detomidine and medetomidine) are likely to be related to their alpha 2 adrenoceptor agonist properties since hypotension and bradycardia were completely antagonized by idazoxan. The decrease in levels of 5-HIAA, induced by these three imidazolic compounds is likely to represent the combination of two additional mechanisms: (i) the stimulation of the alpha 2 adrenoceptors which could contribute to 55% of the decrease observed for the extracellular 5-HIAA and (ii) the interaction with a non-alpha 2 site (through a putative imidazole recognition site), corresponding to the part of the decrease (about 45%) which was not prevented by idazoxan.